Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine
-
Published:2023-02-02
Issue:3
Volume:13
Page:556
-
ISSN:2075-4418
-
Container-title:Diagnostics
-
language:en
-
Short-container-title:Diagnostics
Author:
Rákóczi Éva12, Magócs Gusztáv2, Kovács Sára12, Nagy Béla3ORCID, Szűcs Gabriella1ORCID, Szekanecz Zoltán1ORCID
Affiliation:
1. Department of Rheumatology, Faculty of Medicine, University of Debrecen, 4023 Debrecen, Hungary 2. General Practitioner Service, 4283 Létavértes, Hungary 3. Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4023 Debrecen, Hungary
Abstract
Objectives: In this prospective study, SARS-CoV−2 spike protein specific total immunoglobulin (Ig) levels were analyzed before and after BNT162 b2 mRNA booster vaccination in individuals previously administered with two doses of BBIBP-CorV vaccine in comparison to immunized participants with three doses of BNT162 b2 vaccination. Methods: Sixty-one Caucasian volunteers (39 females, 22 males) vaccinated by BBIBP-CorV were included (mean age: 63.9 years). Sixty-one patients (41 females, 20 males) as controls were vaccinated with BNT162b2 (mean age: 59.9 years). Both groups received the third booster BNT162b2 vaccine. Total anti-SARS-CoV−2 S1-RBD Ig levels were measured by an immunoassay (Roche Diagnostics) and their calculated ratios after/before booster dose were compared between the two groups. Results: At baseline, significantly lower anti-SARS-CoV−2 S1-RBD total antibody levels were determined after initial immunization by two doses of inactivated BBIBP-CorV compared to BNT62b2 mRNA vaccine (p < 0.001). After BNT162b2 boosters, similarly high total Ig levels were detected in both the heterologous (27,195 [15,604–42,754] BAU/mL, p < 0.001) and the homologous booster cohort (24,492 [13,779−42,671] BAU/mL, p < 0.001) compared to baseline. Hence, the ratio of after/before total Ig levels was significantly higher with heterologous vs homologous immunization (p < 0.001). Conclusion: To address the concept that basic BBIBP-CorV vaccination is not as effective as BNT162b, we analyzed the effect of heterologous vaccination with BNT162b2. Our results suggest that BNT162b2 can successfully boost the effects of two-dose BBIBP-CorV vaccination.
Funder
National Research, Development and Innovation Office, and the Hungarian Academy of Sciences
Subject
Clinical Biochemistry
Reference34 articles.
1. (2023, January 05). COVID-19 Coronavirus Pandemic Weekly Trends. Available online: https://www.worldometers.info/coronavirus/. 2. (2023, January 05). Plan of Tasks Related to COVID−19 Vaccination, Available online: http://koronavirus.gov.hu. 3. Safety and immunogenicity of an inactivated SARS-CoV−2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial;Xia;Lancet Infect. Dis.,2021 4. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV−19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV−2 and death due to COVID−19 in people older than 60 years in Argentina: A test-negative, case-control, and retrospective longitudinal study;Rearte;Lancet,2022 5. Alqassieh, R., Suleiman, A., Abu-Halaweh, S., Santarisi, A., Shatnawi, O., Shdaifat, L., Tarifi, A., Al-Tamimi, M., Al-Shudifat, A., and Alsmadi, H. (2021). Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers. Vaccines, 9.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|